This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care
Leukemia Open Access 01 October 2018
-
Preleukemia: one name, many meanings
Leukemia Open Access 30 November 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Germing U, Strupp C, Kuendgen A, Isa S, Knipp S, Hildebrandt B et al. Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. Haematologica 2006; 91: 1596–1604.
Greenberg P, Cox C, Le Beau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088.
Deguchi K, Gilliland DG . Cooperativity between mutations in tyrosine kinases and in hematopoietic transcription factors in AML. Leukemia 2002; 16: 740–744.
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. (eds) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. 2008, International Agency for Research on Cancer (IARC): Lyon.
Chen CY, Lin LI, Tang JL, Ko BS, Tsay W, Chou WC et al. RUNX1 gene mutation in primary myelodysplastic syndrome—the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome. Br J Haematol 2007; 139: 405–414.
Georgiou G, Karali V, Zouvelou C, Kyriakou E, Dimou M, Chrisochoou S et al. Serial determination of FLT3 mutations in myelodysplastic syndrome patients at diagnosis, follow up or acute myeloid leukaemia transformation: incidence and their prognostic significance. Br J Haematol 2006; 134: 302–306.
Acknowledgements
We thank all the coworkers in our laboratory for their excellent technical assistance, as well as all physicians for referring the sample material to our center.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
SS, WK, CH, TH own and are employed by the Munich Leukemia Laboratory (MLL) GmbH. NW, JS, TW and FD are employed by MLL GmbH.
Rights and permissions
About this article
Cite this article
Dicker, F., Haferlach, C., Sundermann, J. et al. Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML. Leukemia 24, 1528–1532 (2010). https://doi.org/10.1038/leu.2010.124
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2010.124
This article is cited by
-
NPM1 Biology in Myeloid Neoplasia
Current Hematologic Malignancy Reports (2020)
-
Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1
Modern Pathology (2020)
-
Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care
Leukemia (2018)
-
Number of RUNX1 mutations, wild-type allele loss and additional mutations impact on prognosis in adult RUNX1-mutated AML
Leukemia (2018)
-
The clonal origins of leukemic progression of myelodysplasia
Leukemia (2017)